ABSTRACT
: The current study aimed to measure the effects of Plasma-Lyte 148 solution on the blood coagulation profile according to the hemodilution level using rotational thromboelastometry (ROTEM) tests. Venous blood was collected from 12 healthy volunteers and divided into four specimen bottles, which were diluted at different levels with Plasma-Lyte 148 (0, 20, 40, and 60%). Following this, ROTEM tests were performed on the study samples. We found that as the hemodilution level increased, the ROTEM values showed a hypocoagulable pattern. The change rate of the maximum clot firmness (MCF) of INTEM was greater in the 40 (Pâ=â0.015) and 60% (Pâ<â0.001) dilutions than it was in the 20% dilution. Greater lengthening of the clot formation time of EXTEM was observed in the 60% dilution than it was in the 20% dilution (Pâ<â0.001). The alpha-angle of EXTEM showed a greater decrease in the 60% dilution than it did in the 20% dilution (Pâ<â0.001). A larger change rate of the MCF of EXTEM was observed in the 40 (Pâ=â0.003) and 60% (Pâ<â0.001) dilutions than it was in the 20% dilution. A greater decrease in the MCF of FIBTEM was identified in the 40 (Pâ=â0.009) and 60% (Pâ<â0.001) dilutions than in the 20% dilution. All coagulation pathways exhibited hypocoagulable patterns as the hemodilution level increased. However, most of the mean values of ROTEM parameters were within the normal reference range, except for those of the 60% dilution.
Subject(s)
Blood Coagulation Tests/methods , Blood Coagulation/drug effects , Female , Gluconates/adverse effects , Humans , Magnesium Chloride/adverse effects , Male , Potassium Chloride/adverse effects , Sodium Acetate/adverse effects , Sodium Chloride/adverse effects , Thrombelastography , VolunteersABSTRACT
We performed a study to investigate whether contamination of hemostasis samples with a glucose-containing solution might generate spurious results in rotational thromboelastometry (ROTEM) tests.Venous blood was taken from 12 healthy volunteers and divided into 4 specimen bottles, which were contaminated with different concentrations (0%, 5%, 10%, and 20%) of glucose solution.Significant lengthening of INTEMCT was observed in the 10% and 20% groups compared with baseline values (7.7% and 9%, Pâ=â0.041 and Pâ=â0.037, respectively). INTEMCFT increased by 20.1% in the 20% group (Pâ=â0.005). INTEMα-angle and INTEMMCF decreased by 3.9% and 2.7%, respectively, in the 20% group (Pâ=â0.010 and Pâ=â0.049, respectively). EXTEMCFT was prolonged significantly, by 10.2%, 15.5%, and 25.6%, in the 5%, 10%, and 20% groups, respectively (Pâ=â0.004, Pâ<â0.001, and Pâ<â0.001, respectively). EXTEMα-angle decreased significantly by 1.9%, 3.2%, and 4.0% in the 5%, 10%, and 20% groups, respectively (Pâ=â0.014, Pâ=â0.001, and Pâ=â0.005, respectively). EXTEMMCF decreased by 3.4% in the 20% group (Pâ=â0.023). FIBTEMMCF decreased by 9.2% and 17.5% in the 10% and 20% groups, respectively (Pâ=â0.019 and Pâ=â0.021, respectively). A significant correlation was observed between standard glucose solution contamination in the specimens and percentage variation of EXTEMCFT, EXTEMMCF, and FIBTEMMCF.To obtain accurate data from the ROTEM test regarding the hemostatic status of patients, specimens with suspected or known contamination should not be analyzed.
Subject(s)
Blood Coagulation , Blood Glucose/analysis , Blood Specimen Collection/methods , Fluid Therapy , Glucose/administration & dosage , Thrombelastography/methods , Adult , Humans , In Vitro Techniques , Infusions, Intra-Arterial , SolutionsABSTRACT
BACKGROUND AND OBJECTIVES: The adverse effects of spinal anesthesia (SA) include arterial hypotension and bradycardia. The aim of this study was to compare the effects of 2 type 3 serotonin receptor antagonists in SA-induced adverse effects. Specifically, we assessed whether ramosetron was more effective than ondansetron in reducing SA-induced decreases in blood pressure (BP) and heart rate (HR). METHODS: A total of 117 patients undergoing orthopedic surgery and receiving SA were intravenously administered 0.3 mg of ramosetron (n = 39, group R), 4 mg of ondansetron (n = 39, group O4), or 8 mg of ondansetron (n = 39, group O8). Systolic BP (SBP), diastolic BP (DBP), mean BP (MBP), HR, and the lowest SBP, DBP, MBP, and HR values were measured preoperatively (baseline) and intraoperatively. The incidence of postoperative nausea and vomiting, the need for rescue antiemetics, the amount of patient-controlled analgesia consumption, and pain score in the first 48 hours after surgery were determined. RESULTS: Baseline values did not significantly differ among the 3 groups. After SA, SBP, DBP, MBP, and HR were lower than their baseline values in all 3 groups. The differences between the baseline and the lowest values were significantly less in group R than in groups O4 and O8 with respect to SBP (P < 0.001), DBP (P = 0.001), and MBP (P < 0.001) less in group R than in group O4 with respect to HR (P = 0.032). Intergroup differences were not significant for postoperative nausea and vomiting, the need for rescue antiemetics, patient-controlled analgesia consumption, or pain score. CONCLUSIONS: The administration of ramosetron (0.3 mg) significantly attenuated the SA-induced decrease in BP compared with 4 or 8 mg of ondansetron and HR compared with 4 mg of ondansetron.
Subject(s)
Anesthesia, Spinal/adverse effects , Benzimidazoles/administration & dosage , Hypotension/drug therapy , Ondansetron/administration & dosage , Preoperative Care/methods , Serotonin Antagonists/administration & dosage , Adult , Aged , Double-Blind Method , Female , Humans , Hypotension/diagnosis , Hypotension/etiology , Male , Middle Aged , Postoperative Nausea and Vomiting/diagnosis , Postoperative Nausea and Vomiting/etiology , Postoperative Nausea and Vomiting/prevention & control , Treatment OutcomeABSTRACT
Glutamate transporters (also called excitatory amino acid transporters, EAAT) participate in maintaining extracellular homeostasis of glutamate, a major excitatory neurotransmitter, and regulating glutamate neurotransmission. EAAT3, the major neuronal EAAT, may also regulate gamma-aminobutyric acid-mediated inhibitory neurotransmission. Dysfunction of EAAT3 has been shown to induce seizure in rats. We hypothesize that carbamazepine, a commonly used antiepileptic agent, enhances EAAT3 activity. We tested this hypothesis using oocytes artificially expressing EAAT3 and C6 rat glioma cells expressing endogenous EAAT3. In oocytes, carbamazepine dose-dependently enhanced EAAT3 activity. The EC50 of this carbamazepine effect was 12.2muM. The concentrations of carbamazepine to significantly enhance EAAT3 activity were within the therapeutic serum levels (17-51muM) of carbamazepine for the antiepileptic effect. Carbamazepine decreased the Km but did not change the maximal response of EAAT3 to glutamate. Carbamazepine-increased EAAT3 activity was inhibited by wortmannin or LY-294002, phosphatidylinositol 3-kinase (PI3K) inhibitors, but was not affected by staurosporine, chelerythrine or calphostin C, protein kinase C inhibitors. In C6 cells, carbamazepine also enhanced the endogenous EAAT3 activity. However, carbamazepine did not affect the activity of EAAT4 expressed in Cos7 cells. These results suggest that carbamazepine at clinically relevant concentrations specifically enhances the affinity of EAAT3 for glutamate to increase EAAT3 activity via a PI3K-dependent pathway. EAAT3 may be a therapeutic target for carbamazepine in the central nervous system.
Subject(s)
Anticonvulsants/administration & dosage , Carbamazepine/administration & dosage , Excitatory Amino Acid Transporter 3/metabolism , Gene Expression Regulation/drug effects , Phosphatidylinositol 3-Kinases/physiology , Animals , Cell Line, Tumor , Chlorocebus aethiops , Dose-Response Relationship, Drug , Drug Interactions , Enzyme Inhibitors/pharmacology , Female , Glioma , Glutamic Acid/metabolism , Glutamic Acid/pharmacology , Membrane Potentials/drug effects , Membrane Potentials/physiology , Oocytes/drug effects , Patch-Clamp Techniques/methods , Phosphoinositide-3 Kinase Inhibitors , Rats , Xenopus laevisABSTRACT
BACKGROUND AND OBJECTIVES: The aim of this study was to determine whether an intrabursal morphine and bupivacaine mixed infusion provides useful analgesia for prolonged pain relief after subacromial arthroscopic operation. METHODS: A continuous intrabursal infusion catheter was inserted at the conclusion of the subacromial arthroscopic operation that was performed under general anesthesia. In a prospective, double-blind, randomized trial, 60 patients were divided into 2 groups: an anesthetic group received 5 mL of mixed 0.5% bupivacaine, 2 mg of morphine, 0.05 mL of 1/1,000 epinephrine as a bolus, and a solution of 40 mL of a 0.5% bupivacaine and 8 mg of morphine mixture that was used as a maintenance dose at a constant rate of 0.5 mL/h. This was done by means of a continuous infusion pump (0.5 mL hourly). A saline group (n = 30) received continuous saline infusion. Two patients were eliminated from the study because of catheter leakage or malfunction in the saline group. The intensity of the pain was evaluated preoperatively and postoperatively for 3 days by a graded visual analog scale (score from 0 to 10) for night pain, pain on motion, sleep disturbance, lying on painful shoulder, and the amounts of supplemental analgesics. RESULTS: Pain was decreased on the first and second postoperative day, and there was less sleep disturbance for 3 days postoperatively in the anesthetic group. There was no difference in pain caused by movement postoperatively. In the anesthetic group, lesser amounts of analgesics were used in the first 48 hours postoperatively. CONCLUSIONS: The continuous intrabursal infusion method resulted in a decreased perception of rest pain and reduced supplemental analgesics requirement for 2 days postoperatively.